Nyxoah ( (NYXH) ) just unveiled an announcement.
Nyxoah reported its financial and operating results for the fourth quarter and full year 2024, highlighting a transformative year marked by the completion of its PMA submission with the FDA for the Genio system and the establishment of a U.S. commercial organization. The company saw an increase in revenue and gross margin, driven by the commercialization of its Genio system, despite an increase in operating loss due to higher R&D and commercialization expenses. Nyxoah is positioned for a U.S. commercial launch in March 2025, pending FDA approval, which is expected by the end of the first quarter.
More about Nyxoah
Nyxoah is a company that develops innovative treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation. The company is focused on commercializing its Genio system, primarily in Germany, and is preparing for a U.S. market launch.
YTD Price Performance: 7.63%
Average Trading Volume: 41,750
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $331M
For detailed information about NYXH stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com